This page contains a Flash digital edition of a book.

Investigating and creating novel treatments for the pain, cancer, scarring and depression that accompanies Crohn’s and colitis. Researcher

Institution Project

Dr. Devendra Amre CHU Ste-Justine Certain chemical changes in a child’s DNA can influence the expression of specific genes that may

serve as markers for diagnosing Crohn’s disease in children and also help predict which child is likely to suffer from complications and require surgery. Dr. Amre is studying the utility of these DNA markers to possibly assist in the implementation of management of Crohn’s disease in children.

Co-Investigator(s): Dr. David Mack

Dr. Colette Deslandres

Dr. Wallace MacNaughton

Children’s Hospital Keywords: DNA methylation; diagnostic markers; of Eastern Ontario pediatric Crohn’

CHU Ste-Justine University

of Calgary s disease; prognostic markers; pediatric.

Proteases are enzymes that break down proteins. Some types of proteases can trigger colonic

inflammation but how this happens is not known. Dr. MacNaughton is studying protease-induced inflammation in order to identify potential targets for the development of drugs to treat IBD. This work may also help to better understand inflammation-associated colorectal cancer, which occurs in some ulcerative colitis patients.

Keywords: colorectal cancer; epithelium; apoptosis; resolution of inflammation; ulcerative colitis.

Dr. Michael Blennerhassett Queen’s University

The enteric nervous system is a large and complex network of nerve cells present throughout the

GI tract, which extend axons to smooth muscle to regulate important intestinal functions. Dr. Blennerhassett is studying how axons and neurons are damaged and how this may lead to stricture formation. Overall, this will improve our understanding of neuron damage and repair in order to prevent stricture formation in IBD.

Keywords: intestine; stricture formation; neurobiology; smooth muscle; inflammation.

Dr. Stephen Vanner

Queen’s University Abdominal pain is a debilitating symptom for many $120,112

patients with IBD and can result in emotional suffering (Year 1 of 3) and physical disability. This pain can be difficult to effectively treat, because its underlying cause isn’t well understood. This complicates the decision on how to treat such pain, and whether to use strong opiate drugs like morphine. Dr. Vanner will study the mechanisms of pain to determine if existing pharmacological agents can prevent these events and to guide doctors in developing effective treatment plans to manage use of pain medications.

Co-Investigator(s): Dr. Alan Lomax

Queen’s University Keywords: abdominal pain; pain management;

neuroimmune interplay; effects of psychological stress; clinical steroids.

$119,418 (Year 3 of 3) $119,445 (Year 3 of 3)

Investment $110,823 (Year 2 of 3)

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32